News & Analysis on Clinical Trial Services & Contract Research And Development
Dr. Shi Yin Foo - Cardioxyl Pharmaceuticals
By Dan Stanton
- Last updated on
Cardioxyl Pharmaceuticals has appointed Dr. Shi Yin Foo - who comes from being responsible for the establishment and execution of multiple novel programs in the cardiorenal space at Novartis - as Chief Medical Officer.
“Her unique combination of both early- and late-stage cardiovascular development experience –combined with her extensive clinical experience in the treatment of patients with heart failure – will serve as an excellent complement to Cardioxyl’s proprietary expertise in the biology, physiology and chemistry of nitroxyl donors,” said CEO Dr. Chris Kroeger.